Skip to content

IAS: ‘Next generation’ NNRTI GW695634 is safe and active in NNRTI-resistant patients

IAS: Needle-free T-20 delivery reduces, but does not eliminate, injection site reactions (corrected)

IAS: Remune slows viral load rise and CD4 cell count fall during treatment interruptions

IAS: New NRTI D-d4FC active in treatment-experienced patients

IAS: Tipranavir combined with T-20 achieves good virologic results in the highly treatment experienced

IAS: Remaining on 3TC despite resistance leads to better immunological and clinical outcomes

IAS: Treatment-related side-effects, sexual dysfunction and parental disapproval linked to sexual risk-taking in gay HIV-positive men

IAS: Growth hormone improves CD4 cell count in patients with a poor response to HAART

IAS: Have we prematurely discarded triple NRTI regimens?